Oruka Therapeutics price target raised to $70 from $40 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Oruka Therapeutics (ORKA) to $70 from $40 and keeps a Buy rating on the shares. The firm says the ORKA-001 EVERLAST-A data readout “appears imminent.” H.C. Wainwright increased its probability of approval for ORKA-001 to 50% in anticipation of positive data from the EVERLAST-A program. In addition, the firm increased its probability of approval for ORKA-002, the company’s second pipeline candidate.